CNTA
Centessa Pharmaceuticals plcCompany Information
- Company Name
- Centessa Pharmaceuticals plc
- CIK
- CIK0001847903
- Category
- <br>Emerging growth company
- Ticker: Exchange
- CNTA: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CNTA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-05-16
- Last sale
- 2026-06-24
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 30,575,733
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 146,925,740
- Shares outstanding
- 153,549,733
- Ownership
- 95.69%
Earnings Market Reaction
- Filing date
- 2026-05-05
- Price on filing date
- —
- 1-month reaction
- 0.23%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 62 | 61 | 51 | 44 | 105 | 383 | 395 | 127 | 118 | 128 | 171 | 145 | ||||||
| Short Term Investments | 214 | 233 | 195 | 206 | 179 | 99 | 123 | 167 | 112 | 129 | 110 | 158 | ||||||
| Prepaid Expense And Other Assets Current | 16 | 19 | 12 | 9 | 14 | 10 | 16 | 19 | 18 | 21 | 23 | 20 | ||||||
| Assets Current | 349 | 368 | 308 | 300 | 348 | 536 | 568 | 356 | 284 | 315 | 332 | 350 | ||||||
| Debt Securities Available For Sale Excluding Accrued Interest Noncurrent | 257 | 283 | 103 | 153 | 140 | 0 | - | - | - | - | - | - | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 10 | 10 | 10 | 11 | 11 | 11 | 11 | 11 | 12 | 12 | 12 | 12 | ||||||
| Deferred Income Tax Assets Net | 24 | 25 | 25 | 25 | 26 | 27 | 27 | 29 | 29 | 30 | 30 | 27 | ||||||
| Other Assets Noncurrent | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | ||||||
| Assets | 642 | 687 | 448 | 492 | 528 | 577 | 610 | 399 | 328 | 360 | 377 | 393 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 11 | 8 | 9 | 6 | 5 | 7 | 7 | 5 | 7 | 12 | 11 | 11 | ||||||
| Accrued Liabilities Current | 26 | 35 | 20 | 24 | 19 | 51 | 19 | 21 | 20 | 28 | 24 | 23 | ||||||
| Liabilities Current | 37 | 43 | 29 | 30 | 24 | 58 | 26 | 27 | 27 | 39 | 35 | 34 | ||||||
| Long Term Debt Noncurrent | 110 | 110 | 110 | 110 | 109 | 109 | 76 | 77 | 77 | 76 | 74 | 73 | ||||||
| Operating Lease Liability Noncurrent | 7 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 9 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Liabilities | 154 | 161 | 147 | 147 | 142 | 175 | 111 | 112 | 113 | 124 | 118 | 116 | ||||||
Statement Of Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,751 | 1,710 | 1,419 | 1,408 | 1,399 | 1,386 | 1,374 | 1,120 | 1,004 | 987 | 974 | 953 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 3 | 3 | 2 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | ||||||
| Retained Earnings Accumulated Deficit | -1,265 | -1,186 | -1,120 | -1,065 | -1,015 | -989 | -877 | -835 | -791 | -753 | -716 | -677 | ||||||
| Stockholders Equity | 487 | 527 | 302 | 345 | 386 | 402 | 499 | 287 | 215 | 236 | 259 | 277 | ||||||
| Liabilities And Stockholders Equity | 642 | 687 | 448 | 492 | 528 | 577 | 610 | 399 | 328 | 360 | 377 | 393 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 222 | 184 | 222 | 222 | 184 | 184 | 184 | 184 | 153 | 184 | 153 | 153 | ||||||
| Common Stock Shares Issued | 155 | 149 | 134 | 134 | 134 | 133 | 132 | 113 | 100 | 99 | 98 | 95 | ||||||
| Shares Outstanding | 155 | 149 | 134 | 134 | 134 | 133 | 132 | 113 | 100 | 99 | 98 | 95 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCentessa Pharmaceuticals plc (CNTA) — SEC Financial Statements & Analysis
Centessa Pharmaceuticals plc (CNTA) is a pharmaceutical preparations company, incorporated in X0. Centessa Pharmaceuticals plc trades on Nasdaq as: CNTA. Centessa Pharmaceuticals plc (CNTA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-05. Based on that filing, On profitability, Centessa Pharmaceuticals plc posts an operating margin of -1384.61%, a net margin of -1316.88%, a Return on Equity (ROE) of -57.38%, a Return on Assets (ROA) of -42.86%, and a Return on Invested Capital (ROIC) of -55.48%. Per share, it reports EPS of $-1.63, diluted EPS of $-1.63, free cash flow per share of $-1.36, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 11.97% year-over-year, and EPS growth of -2.99% year-over-year. On the balance sheet, it maintains a current ratio of 9.53x, a quick ratio of 9.11x, working capital of $312.11M, a debt-to-equity ratio of 0.32x, a debt ratio of 0.24, an interest coverage ratio of -22.69x, free cash flow of $-209.17M (TTM), and net debt of $47.35M. Figures sourced from SEC EDGAR.
- EPS TTM
- $-1.63
- ROE TTM
- -57.38%
- ROA TTM
- -42.86%
- Debt To Equity
- 0.32x
- Free Cash Flow TTM
- $-209.17M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Centessa Pharmaceuticals plc in?
Centessa Pharmaceuticals plc (CNTA) operates in the Pharmaceutical Preparations industry.
What exchange does CNTA trade on?
Centessa Pharmaceuticals plc (CNTA) trades on the Nasdaq.
Where is Centessa Pharmaceuticals plc incorporated?
Centessa Pharmaceuticals plc is incorporated in United Kingdom.
When was Centessa Pharmaceuticals plc (CNTA)'s most recent SEC filing?
Centessa Pharmaceuticals plc (CNTA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-03-31, filed with the SEC on 2026-05-05.
What is CNTA's EPS (earnings per share)?
Centessa Pharmaceuticals plc (CNTA)'s trailing twelve month EPS is $-1.63 as of 2026-03-31.
What is CNTA's ROE (return on equity)?
Centessa Pharmaceuticals plc (CNTA)'s trailing twelve month Return on Equity (ROE) is -57.38% as of 2026-03-31.
What is CNTA's ROA (return on assets)?
Centessa Pharmaceuticals plc (CNTA)'s trailing twelve month Return on Assets (ROA) is -42.86% as of 2026-03-31.
What is CNTA's ROIC (return on invested capital)?
Centessa Pharmaceuticals plc (CNTA)'s trailing twelve month Return on Invested Capital (ROIC) is -55.48% as of 2026-03-31.